Amid increasing federal oversight of the Bio/Med industry, MedTech is making New York’s voice heard. By supporting policy changes that will promote industry growth and innovation in New York State, MedTech is protecting the state’s ability to compete nationally and worldwide.
MedTech works closely with national organizations AdvaMed, BIO, MDMA and PhRMA to advocate for shared policy objectives and ensure that New York companies’ voices are heard by federal elected officials.
Legislative Update (2/21/17)
This downloadable document highlights legislative updates for the following focus areas:
Ending Regulations and Reversing the Obama Administration's Rules
Budget and Appropriations
Medical Device Tax Repeal
21st Century Cures Act
Small Business HRAs
Tax Changes for Entrepreneurs and Startups
- Science and Technology
21st Century Cures Act Update
The 21st Century Cures Act was officially signed into law on December 13th, 2016 by President Obama, marking a rare show of bipartisan cooperation in the final days of the 114th Congress. This nearly 1,000 page piece of healthcare legislation houses numerous FDA regulations speeding up the approval process of new drugs and medical devices, authorizes funding for new and existing research programs within the NIH, and highlights emerging HHS priorities within mental health and opioid abuse, regenerative medicine, and precision medicine.
This downloadable report contains regulatory items organized by subject matter, as well as an overview of new funding authorized by the Act.